𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dideoxyinosine for chronic hepatitis B infection

✍ Scribed by Adrian P. Catterall; Graham J. Moyle; Elaine A. Hopes; Tim J. Harrison; Brian G. Gazzard; Iain M. Murray-Lyon

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
270 KB
Volume
37
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Six patients positive for both human immunodeficiency virus (HIV) and hepatitis B were studied to assess the effect of dideoxyinosine (DDI) on hepatitis B virus (HBV) replication. Two patients died during the follow‐up period and four had at least 8 weeks of therapy. One patient demonstrated HBV DNA suppression and became transiently negative. In the remaining five patients, there was no appreciable change in HBV DNA levels during DDI therapy. DDI was well tolerated in all patients, the only significant side effect being diarrhoea.

It is concluded that DDI has no notable antiviral effect in patients with chronic HBV infection when coinfected with HIV. Β© 1992 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

A pilot study of 2β€²,3β€²-dideoxyinosine fo
A pilot study of 2β€²,3β€²-dideoxyinosine for the treatment of chronic hepatitis B
✍ Michael W. Fried; Julia C. Korenman; Adrian M. Di Bisceglie; Yoon Park; Jeanne G πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 449 KB πŸ‘ 1 views

The nucleoside analog 2',3'-dideoxyinosine, currently being used to treat patients infected with the human immunodeficiency virus, has been shown to inhibit viral replication in certain cell culture systems of hepatitis B virus and the duck model of chronic hepatitis B infection. We studied the effe

Acyclovir in chronic hepatitis B virus i
Acyclovir in chronic hepatitis B virus infection
✍ Geoffrey M. Dusheiko πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 273 KB πŸ‘ 2 views

In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 pati

AFP in chronic hepatitis B virus infecti
AFP in chronic hepatitis B virus infection
✍ Yun-Fan Liaw; Anna Lok πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 151 KB πŸ‘ 2 views

to be controlled for in comparing immunoprophylactic approaches. At present, DNA polymerase activity or HBV DNA is useful for estimating the level of exposure. In an editorial in this issue, Dr. Dienstag pointed out difficulties in comparing the results of two immunoprophylactic regimens conducted a

Hepatitis A Infection in Chronic Carrier
Hepatitis A Infection in Chronic Carriers of Hepatitis B Virus
✍ Reinhart Zachoval; Michael Roggendorf; Friedrich Deinhardt πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 441 KB πŸ‘ 2 views

By routine screening for serologic markers of hepatitis A and B in patients with acute hepatitis, 30 chronic carriers of hepatitis B virus with serologic evidence of acute hepatitis A and two patients with simultaneous acute infection with hepatitis A virus and hepatitis B virus were detected. For